Drug
Tucidinostat clinical trials
Also written Chidamide, Epidaza, HBI-8000 and CS055.
- studies test it
- 160
- open now
- 73
- in phase 3
- 13
- first study started
- 2013
Keep track of what changes. Save the tucidinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
160 studies that test it; most in 2022 (27)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 14 |
| 2017 | 9 |
| 2018 | 9 |
| 2019 | 8 |
| 2020 | 10 |
| 2021 | 16 |
| 2022 | 27 |
| 2023 | 15 |
| 2024 | 18 |
| 2025 | 12 |
| 2026 | 15 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 37
- Phase 2
- 134
- Phase 3
- 13
- Phase 4
- 2
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 143
Sun Yat-sen University (19) · Chinese PLA General Hospital (11) · Chipscreen Biosciences, Ltd. (9) · Ruijin Hospital (9) · Tianjin Medical University Cancer Institute and Hospital (6) · The First Affiliated Hospital of Soochow University (6) · Peking Union Medical College Hospital (6) · Sichuan University (6)
Often tested with
Tested in the same studies.
Azacitidine (17) · Sintilimab (12) · Venetoclax (10) · Gemcitabine (7) · Decitabine (7) · Camrelizumab (6) · Toripalimab (5) · Cytarabine (5)
Studies
Open first, then newest update. How each study uses tucidinostat is read from its arms, and is right about nine times in ten.
Testing it · 160
- Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT06947967Written as Tucidinostat
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07159620Written as Chidamide
- A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) ExpressionRecruitingPhase 2Guangdong Association of Clinical TrialsNCT07412262Written as Chidamide in combination with Ivonescimab
- Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaRecruitingPhase 3Chinese PLA General HospitalNCT07514936Written as Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
- Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/LymphomaNot yet recruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT07774377Written as Chidamide
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingPhase 1/2Peking Union Medical College HospitalNCT07754890Written as Chidamide
- The Efficacy of CAPCT in Patients With PTCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07746245Written as Chidamide
- Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06570447Written as Chidamide
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07397832Written as Chidamide
- Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)RecruitingPhase 2Great Novel Therapeutics Biotech & Medicals CorporationNCT05833724Written as Chidamide
- Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia RelapseRecruitingPhase 1/2Zhujiang HospitalNCT05270200Written as Chidamide
- Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRecruitingPhase 2Rong TaoNCT07507318Written as Chidamide
- Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic SyndromesNot yet recruitingPhase 2Zhongshan Hospital (Xiamen), Fudan UniversityNCT07616336Written as Chidamide
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07601607Written as Chidamide
- Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingPhase 2Liling ZhangNCT05976997Written as Duvelisib, Chidamide
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsRecruitingPhase 2Chinese PLA General HospitalNCT06928376Written as Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaRecruitingPhase 2Shanghai Zhongshan HospitalNCT07570849Written as Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor
- Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After RadiotherapyRecruitingPhase 1West China HospitalNCT07545967Written as Chidamide
- Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT07518602Written as Chidamide
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Chidamide
See all 160 studies that test tucidinostat →
Given in every arm · 6 — tucidinostat is usual care beside what is tested
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingPhase 2Ruijin HospitalNCT07380984Written as Chidamide
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Chidamide
- Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorNot yet recruitingPhase 2Beijing 302 HospitalNCT06556862Written as Chidamide
- APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT05186012Written as Chidamide
- Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingPhase 2Sun Yat-sen UniversityNCT04724239Written as Chidamide
- A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast CancerStatus unknownPhase 2Fudan UniversityNCT05438706Written as chidamide
As the comparator · 2 — what is tested is compared with tucidinostat
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingPhase 3Dizal PharmaceuticalsNCT07234162Written as Chidamide
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLActive, not recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04668690Written as Chidamide
Codes
What other systems call tucidinostat · ClinicalTrials.gg INT005587
- MeSH (NLM) C547816N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideConfirmed NLM, Wikidata
- UNII (FDA) 87CIC980Y0TUCIDINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q19903814tucidinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97263TucidinostatOne source FDA
- DrugBank DB06334One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547816 | N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide | Confirmed NLM, Wikidata |
| UNII (FDA) | 87CIC980Y0 | TUCIDINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19903814 | tucidinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97263 | Tucidinostat | One source FDA |
| DrugBank | DB06334 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.